New insights for the development of efficient DNA vaccines

IF 5.7 2区生物学 Microbial Biotechnology Pub Date : 2024-11-15 DOI:10.1111/1751-7915.70053

Simone Berger, Yanira Zeyn, Ernst Wagner, Matthias Bros

{"title":"New insights for the development of efficient DNA vaccines","authors":"Simone Berger, Yanira Zeyn, Ernst Wagner, Matthias Bros","doi":"10.1111/1751-7915.70053","DOIUrl":null,"url":null,"abstract":"<p>Despite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical treatment is far behind the expectations up to now. The main reason is the poor immunogenicity of DNA vaccines in humans. Consequently, the improvement of the performance of DNA vaccines in vivo is required. This mini-review provides an overview of the current state of DNA vaccines and the various strategies to enhance the immunogenic potential of DNA vaccines, including (i) the optimization of the DNA construct itself regarding size, nuclear transfer and transcriptional regulation; (ii) the use of appropriate adjuvants; and (iii) improved delivery, for example, by careful choice of the administration route, physical methods such as electroporation and nanomaterials that may allow cell type-specific targeting. Moreover, combining nanoformulated DNA vaccines with other immunotherapies and prime-boost strategies may help to enhance success of treatment.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"17 11","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1751-7915.70053","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1751-7915.70053","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Despite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical treatment is far behind the expectations up to now. The main reason is the poor immunogenicity of DNA vaccines in humans. Consequently, the improvement of the performance of DNA vaccines in vivo is required. This mini-review provides an overview of the current state of DNA vaccines and the various strategies to enhance the immunogenic potential of DNA vaccines, including (i) the optimization of the DNA construct itself regarding size, nuclear transfer and transcriptional regulation; (ii) the use of appropriate adjuvants; and (iii) improved delivery, for example, by careful choice of the administration route, physical methods such as electroporation and nanomaterials that may allow cell type-specific targeting. Moreover, combining nanoformulated DNA vaccines with other immunotherapies and prime-boost strategies may help to enhance success of treatment.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

开发高效 DNA 疫苗的新见解。

尽管 DNA 疫苗在预防感染、治疗自身免疫和过敏性疾病以及癌症免疫疗法等广泛领域具有巨大的应用潜力，但迄今为止，此类疗法在临床治疗中的应用远远落后于人们的期望。主要原因是 DNA 疫苗在人体中的免疫原性较差。因此，需要改善 DNA 疫苗在体内的表现。本微型综述概述了 DNA 疫苗的现状以及提高 DNA 疫苗免疫原性潜力的各种策略，包括：(i) 优化 DNA 构建物本身的大小、核转移和转录调控；(ii) 使用适当的佐剂；(iii) 改进给药方式，例如，谨慎选择给药途径、电穿孔等物理方法以及可实现细胞特异性靶向的纳米材料。此外，将纳米 DNA 疫苗与其他免疫疗法和增效策略结合起来，可能有助于提高治疗的成功率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Microbial Biotechnology Immunology and Microbiology-Applied Microbiology and Biotechnology

CiteScore

11.20

自引率

3.50%

发文量

162

审稿时长

1 months

期刊介绍： Microbial Biotechnology publishes papers of original research reporting significant advances in any aspect of microbial applications, including, but not limited to biotechnologies related to: Green chemistry; Primary metabolites; Food, beverages and supplements; Secondary metabolites and natural products; Pharmaceuticals; Diagnostics; Agriculture; Bioenergy; Biomining, including oil recovery and processing; Bioremediation; Biopolymers, biomaterials; Bionanotechnology; Biosurfactants and bioemulsifiers; Compatible solutes and bioprotectants; Biosensors, monitoring systems, quantitative microbial risk assessment; Technology development; Protein engineering; Functional genomics; Metabolic engineering; Metabolic design; Systems analysis, modelling; Process engineering; Biologically-based analytical methods; Microbially-based strategies in public health; Microbially-based strategies to influence global processes